The SELECT trial demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

People on weight-loss drugs often lose muscle mass while they lose weight, but new scientific findings suggest boosting your ...

Table of Contents The Real Story Behind Your Changing Body Making Every Bite Count When You’re Eating Less Your Brain […] The ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Women and older adults using semaglutide, a popular anti-obesity medication, may face a heightened risk of muscle loss. A ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

If all the Instagram posts and podcasts filling my feed are any indication, lots of 40- and 50-something women are spending ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...